NO20041186L - Diagnostiske eller terapeutiske somatostatin- eller bombesinanalogkonjugater og anvendelser derav - Google Patents

Diagnostiske eller terapeutiske somatostatin- eller bombesinanalogkonjugater og anvendelser derav

Info

Publication number: NO20041186L
Authority: NO; Norway
Prior art keywords: diagnostic; bombesin analog; analog conjugates; therapeutic somatostatin; somatostatin
Prior art date: 2001-09-21

Application number

NO20041186A

Other languages

English (en)

Norwegian (no)

Inventor

William Andrew Murphy

David H Coy

Joseph A Fuselier

Sun Lichun

Original Assignee

Univ Tulane

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-21

Filing date

2004-03-22

Publication date

2004-05-05

2004-03-22 Application filed by Univ Tulane filed Critical Univ Tulane

2004-05-05 Publication of NO20041186L publication Critical patent/NO20041186L/no

Links

102000005157 Somatostatin Human genes 0.000 title 1
108010056088 Somatostatin Proteins 0.000 title 1
DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 title 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title 1
229960000553 somatostatin Drugs 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Percussion Or Vibration Massage (AREA)

NO20041186A 2001-09-21 2004-03-22 Diagnostiske eller terapeutiske somatostatin- eller bombesinanalogkonjugater og anvendelser derav NO20041186L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US32385101P	2001-09-21	2001-09-21
PCT/US2002/030143 WO2003028527A2 (en)	2001-09-21	2002-09-20	Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof

Publications (1)

Publication Number	Publication Date
NO20041186L true NO20041186L (no)	2004-05-05

Family

ID=23260992

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20041186A NO20041186L (no)	2001-09-21	2004-03-22	Diagnostiske eller terapeutiske somatostatin- eller bombesinanalogkonjugater og anvendelser derav

Country Status (16)

Country	Link
US (1)	US7326685B2 (is)
EP (1)	EP1435826A4 (is)
JP (1)	JP4799820B2 (is)
KR (1)	KR20040047846A (is)
CN (1)	CN1589151A (is)
AU (1)	AU2002341792B2 (is)
BR (1)	BR0212897A (is)
CA (1)	CA2461099A1 (is)
IL (2)	IL160993A0 (is)
IS (1)	IS7189A (is)
MX (1)	MXPA04002621A (is)
NO (1)	NO20041186L (is)
NZ (1)	NZ532204A (is)
PL (1)	PL369336A1 (is)
WO (1)	WO2003028527A2 (is)
ZA (1)	ZA200402698B (is)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6721705B2 (en) *	2000-02-04	2004-04-13	Webley Systems, Inc.	Robust voice browser system and voice activated device controller
BR0308090A (pt)	2002-03-01	2006-04-11	Univ Tulane	conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos
US8060626B2 (en) *	2008-09-22	2011-11-15	Sony Computer Entertainment America Llc.	Method for host selection based on discovered NAT type
US7977049B2 (en) *	2002-08-09	2011-07-12	President And Fellows Of Harvard College	Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
CA2523197C (en) *	2003-04-22	2016-05-24	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Peptide vectors
US20060025337A1 (en) *	2003-07-01	2006-02-02	President And Fellows Of Harvard College	Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
US20050096256A1 (en) *	2003-07-01	2005-05-05	President And Fellows Of Harvard College	Compositions for manipulating the lifespan and stress response of cells and organisms
US8017634B2 (en)	2003-12-29	2011-09-13	President And Fellows Of Harvard College	Compositions for treating obesity and insulin resistance disorders
CN101247793B (zh)	2003-12-29	2013-04-10	哈佛大学校长及研究员协会	治疗或预防肥胖和胰岛素抗性病症的组合物
US20050255045A1 (en) *	2004-05-13	2005-11-17	Woltering Eugene A	Surgical marking composition and method
EP1744787A4 (en) *	2004-05-14	2011-04-06	Interface Biologics Inc	POLYMER COUPLING AGENTS AND PHARMACEUTICALLY ACTIVE POLYMERS MANUFACTURED THEREOF
CA2467321A1 (en) *	2004-05-14	2005-11-14	Paul J. Santerre	Polymeric coupling agents and pharmaceutically-active polymers made therefrom
EP1765316A2 (en) *	2004-06-16	2007-03-28	The President and Fellows of Harvard College	Methods and compositions for modulating bax-ku70-mediated apoptosis
US20060014705A1 (en) *	2004-06-30	2006-01-19	Howitz Konrad T	Compositions and methods for selectively activating human sirtuins
WO2006138418A2 (en) *	2005-06-14	2006-12-28	President And Fellows Of Harvard College	Improvement of cognitive performance with sirtuin activators
JP5235662B2 (ja) *	2005-06-16	2013-07-10	ミリアドジェネティクス，インコーポレイテッド	薬学的組成物およびその使用
WO2007097318A1 (ja) *	2006-02-23	2007-08-30	Adeka Corporation	診断用マーカー
DE102006035083A1 (de) *	2006-07-28	2008-01-31	medac Gesellschaft für klinische Spezialgeräte mbH	Proteinbindende Methotrexat-Derivate und diese enthaltende Arzneimittel
US8691761B2 (en)	2006-10-16	2014-04-08	Jean E. F. Rivier	Somatostatin receptor 2 antagonists
PL2383289T3 (pl)	2006-10-16	2015-03-31	Salk Inst Biological Studies	Antagoniści somatostatyny selektywni względem receptora (SSTR2)
EP2084178B1 (en)	2006-10-20	2011-12-07	Ipsen Pharma S.A.S.	Peptide-cytotoxic conjugates
WO2008124828A1 (en) *	2007-04-10	2008-10-16	Myriad Genetics, Inc.	Methods for treating vascular disruption disorders
KR20100016385A (ko) *	2007-04-10	2010-02-12	미리어드 파마슈티칼스, 인코포레이티드	뇌종양 치료방법
EP2144886A4 (en) *	2007-04-10	2012-10-03	Myrexis Inc	METHOD OF TREATING MELANOMA
AU2008236997A1 (en) *	2007-04-10	2008-10-16	Myrexis, Inc.	Methods for treating cancer
NZ580868A (en) *	2007-04-10	2011-07-29	Myriad Pharmaceuticals Inc	Dosages and methods for the treatment of cancer
US9358272B2 (en)	2011-02-17	2016-06-07	The Administrators Of The Tulane Educational Fund	Multicomponent compositions and their uses
JP6501270B2 (ja)	2013-03-14	2019-04-17	ザカリフォルニアインスティテュートフォーバイオメディカルリサーチ	標的化剤抗体抱合体およびその使用
CN109069635B (zh)	2016-02-04	2023-09-26	斯克利普斯研究所	人源化抗cd3抗体、偶联物及其用途
US11279732B2 (en)	2016-02-09	2022-03-22	Cdrd Ventures Inc.	Somatostatin receptor antagonist compounds and methods of using the same
JP7123399B2 (ja)	2016-03-24	2022-08-23	ザアドミニストレイターズオブザテューレインエデュケイショナルファンド	タクロリムスのコンジュゲート、その組成物およびその使用
CA3119793A1 (en) *	2017-11-28	2019-08-01	Board Of Regents Of The University Of Nebraska	Radiopharmaceuticals and methods of use thereof
WO2019148294A1 (en)	2018-02-02	2019-08-08	Interface Biologics, Inc.	Dimeric dexamethasone prodrug compositions and uses thereof
US20210000988A1 (en) *	2018-03-15	2021-01-07	Osaka University	Pharmaceutical composition containing 211at-labeled amino acid derivative, and method for producing said pharmaceutical composition
US12473326B2 (en)	2019-02-01	2025-11-18	Ripple Therapeutics Corporation	Crystalline forms of dexamethasone dimers and uses thereof
US20220347305A1 (en)	2019-08-07	2022-11-03	Ripple Therapeutics Corporation	Controlled release drug dimers
WO2021220061A2 (en)	2020-05-01	2021-11-04	Ripple Therapeutics Corporation	Heterodimer compositions and methods for the treatment of ocular disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4904642A (en)	1985-09-12	1990-02-27	The Administrators Of The Tulane Educational Fund	Therapeutic somatostatin analogs
US4812590A (en)	1987-06-25	1989-03-14	Merck & Co., Inc.	Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US5073541A (en)	1987-11-18	1991-12-17	Administrators Of The Tulane Educational Fund	Treatment of small cell lung cancer with somatostatin analogs
US5753627A (en)	1988-12-05	1998-05-19	Novartis Ag	Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis
US5633263A (en)	1989-04-26	1997-05-27	The Administrators Of The Tulane Educational Fund	Linear somatostatin analogs
DE69018226T2 (de)	1989-07-20	1995-09-21	Sandoz-Patent-Gmbh, 79539 Loerrach	Markierte polypeptidderivate.
ATE124054T1 (de) *	1990-04-06	1995-07-15	Univ Tulane	Somatostatinanaloge.
US5443815A (en)	1991-11-27	1995-08-22	Diatech, Inc.	Technetium-99m labeled peptides for imaging
US5411943A (en)	1992-02-25	1995-05-02	Biomeasure, Inc.	Hepatoma treatment with somatostatin analogs
US5620675A (en) *	1992-06-23	1997-04-15	Diatech, Inc.	Radioactive peptides
US5597894A (en)	1995-06-05	1997-01-28	The Louisiana State University Medical Center Foundation	Multi-tyrosinated somatostatin analogs
US5770687A (en)	1995-06-07	1998-06-23	Peptor Limited	Comformationally constrained backbone cyclized somatostatin analogs
US6051554A (en)	1995-06-07	2000-04-18	Peptor Limited	Conformationally constrained backbone cyclized somatostatin analogs
US5708135A (en)	1995-09-29	1998-01-13	Biomeasure Incorporated	Cyclic peptide analogs of somatostatin
US5750499A (en)	1995-10-18	1998-05-12	The Salk Institute For Biological Studies	Receptor-selective somatostatin analogs
US5843903A (en)	1995-11-27	1998-12-01	The Administrators Of The Tulane Educational Fund	Targeted cytotoxic anthracycline analogs
US6156725A (en)	1996-08-16	2000-12-05	National Institute Of Immunology	Drug for the treatment of cancer
EP0977579B1 (en)	1997-04-22	2009-03-11	Curator Of The University Of Missouri	Gastrin receptor-avid peptide conjugates
AU4267700A (en)	2000-01-13	2001-07-19	Academia Sinica	Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
NZ530007A (en) *	2001-06-08	2006-02-24	Sod Conseils Rech Applic	Somatostatin-dopamine chimeric analogues that retain both somatostatin and dopamine activity in vivo and display enhanced biological activity

2002
- 2002-09-20 PL PL02369336A patent/PL369336A1/xx not_active Application Discontinuation
- 2002-09-20 CN CNA028230817A patent/CN1589151A/zh active Pending
- 2002-09-20 IL IL16099302A patent/IL160993A0/xx unknown
- 2002-09-20 EP EP02775944A patent/EP1435826A4/en not_active Withdrawn
- 2002-09-20 AU AU2002341792A patent/AU2002341792B2/en not_active Ceased
- 2002-09-20 KR KR10-2004-7004173A patent/KR20040047846A/ko not_active Ceased
- 2002-09-20 US US10/490,326 patent/US7326685B2/en not_active Expired - Fee Related
- 2002-09-20 JP JP2003531872A patent/JP4799820B2/ja not_active Expired - Fee Related
- 2002-09-20 CA CA002461099A patent/CA2461099A1/en not_active Abandoned
- 2002-09-20 MX MXPA04002621A patent/MXPA04002621A/es active IP Right Grant
- 2002-09-20 NZ NZ532204A patent/NZ532204A/en not_active IP Right Cessation
- 2002-09-20 BR BR0212897-7A patent/BR0212897A/pt not_active IP Right Cessation
- 2002-09-20 WO PCT/US2002/030143 patent/WO2003028527A2/en not_active Ceased
2004
- 2004-03-19 IS IS7189A patent/IS7189A/is unknown
- 2004-03-21 IL IL160993A patent/IL160993A/en not_active IP Right Cessation
- 2004-03-22 NO NO20041186A patent/NO20041186L/no not_active Application Discontinuation
- 2004-04-06 ZA ZA200402698A patent/ZA200402698B/en unknown

Also Published As

Publication number	Publication date
NZ532204A (en)	2006-04-28
WO2003028527A3 (en)	2003-10-30
PL369336A1 (en)	2005-04-18
JP4799820B2 (ja)	2011-10-26
IL160993A (en)	2011-04-28
IL160993A0 (en)	2004-08-31
US7326685B2 (en)	2008-02-05
WO2003028527A2 (en)	2003-04-10
BR0212897A (pt)	2004-08-24
WO2003028527A8 (en)	2004-04-15
JP2005505580A (ja)	2005-02-24
CA2461099A1 (en)	2003-04-10
ZA200402698B (en)	2005-04-25
AU2002341792B2 (en)	2007-09-06
EP1435826A4 (en)	2009-07-15
EP1435826A2 (en)	2004-07-14
IS7189A (is)	2004-03-19
MXPA04002621A (es)	2004-07-08
KR20040047846A (ko)	2004-06-05
CN1589151A (zh)	2005-03-02
US20050070470A1 (en)	2005-03-31

Legal Events

Date	Code	Title	Description
2012-04-30	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
IL160993A0 (en)	2004-08-31	Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
DK1404809T3 (da)	2014-03-17	Forbedrede hudsubstitutter og anvendelser deraf
DK2336167T3 (da)	2019-09-02	MHC-molekylkonstrukter og deres anvendelse til diagnose og terapi
NO20040246L (no)	2004-04-01	TACI'er- og BR3-polypeptider og anvendelser derav
DK1417175T3 (da)	2013-10-28	Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
NO20044192L (no)	2004-10-04	17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater
DE10295851T1 (de)	2003-12-24	Dachfensterbaueinheit und Einzelteile
NO20014560D0 (no)	2001-09-19	Quinasoliner og terapautisk anvendelse derav
DE60235204D1 (de)	2010-03-11	Medizinische leitung und leitungsverbindungssystem
AU2003228445A8 (en)	2003-10-27	Tissue composites and uses thereof
NO20030832L (no)	2003-04-22	Kondenserte sykliske forbindelser og medisinsk anvendelse derav
NO20034159D0 (no)	2003-09-18	Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
EP1545599A4 (en)	2006-04-05	IMMUNOGENIC COMPOSITIONS AND ITS DIAGNOSTIC AND THERAPEUTIC USES
DE60209310D1 (de)	2006-04-27	Aliphatishe Polyesterzusammensetzung und biegsame Erzeugnisse
DE60205718D1 (de)	2005-09-29	Flexibler wellschlauch und anschlussverfahren
EP1572741A4 (en)	2006-09-27	DIAGNOSTIC AND THERAPEUTIC AGENTS
IS7577A (is)	2004-12-01	Arómatísk súlfón og læknisfræðileg notkun þeirra
AU2002303261A8 (en)	2006-11-02	Gene brcc2 and diagnostic and therapeutic uses thereof
IS2841B (is)	2013-08-15	Samstæða hluta og lyfjasamsetningar
NO20033123L (no)	2003-09-03	Terapeutisk hinne dannende sammensetning og behandlingsplan derav
DK1417189T3 (da)	2006-05-08	Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
EP1462455A4 (en)	2008-12-31	NOVEL PEPTIDES AND THEIR USES AS MEDICAMENTS
DK1556382T3 (da)	2008-10-06	3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
NO20042693L (no)	2004-08-25	Kateterpreparat og anvendelser derav
DK1456377T3 (da)	2019-09-23	Syn3-sammensætninger og fremgangsmåder